Anti-gene strategies to down-regulate gene expression in mammalian cells

Current Pharmaceutical Design

Volumn 10, Issue 7, 2004, Pages 805-819

  Xodo, L E ^a   Cogoi, S ^a   Rapozzi, V ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Antigene strategies; Cell cultures; Oncogenes; PEG conjugated TFO; Peptide nucleic acid; Triple helix oligonucleotides

Indexed keywords

1,3 PROPANEDIAMINE; ANION; ANTISENSE OLIGONUCLEOTIDE; APTAMER; BCR ABL PROTEIN; COMPLEMENTARY DNA; COMPLEMENTARY RNA; DNA; ENZYME INHIBITOR; ETOMIDATE; INTERCALATING AGENT; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MORPHOLINE DERIVATIVE; MYC PROTEIN; NUCLEASE; OLIGODEOXYRIBONUCLEOSIDE METHYLPHOSPHONATE; OLIGONUCLEOTIDE; ONCOPROTEIN; PEPTIDE NUCLEIC ACID; PHOSPHOROTHIOIC ACID DERIVATIVE; POLYAMIDE; POTASSIUM ION; PROTEIN BCL 2; PURINE; RAS PROTEIN; RIBOZYME; SMALL INTERFERING RNA; TIOGUANINE; UNINDEXED DRUG;

BINDING AFFINITY; CANCER GENETICS; CELL CULTURE; DNA HELIX; DNA SEQUENCE; DOWN REGULATION; DRUG BINDING; DRUG CONJUGATION; DRUG HALF LIFE; DRUG RESEARCH; DRUG SELECTIVITY; DRUG USE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE REPRESSION; GENE THERAPY; HUMAN; MAMMAL CELL; MEDICAL LITERATURE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT PLANNING; TRIPLE HELIX;

ANIMALS; CELLS; DNA; DOWN-REGULATION; GENE THERAPY; HUMANS; MAMMALS; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES; PEPTIDE NUCLEIC ACIDS; POLYETHYLENE GLYCOLS;

EID: 1442276558     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043452983     Document Type: Review

References (128)

1. Giovannangeli C, Hélène C. Triplex-forming molecules for modulation of DNA information processing. Curr Opin Mol Ther 2000; 2: 288-96.
2. Vasquez KM, Wilson JH. Triplex-directed modification of genes and gene activit. Trends Biochem Sci 1988; 23: 4-9.
3. Guntaka RV, Varina BR, Weber KT. Triplex-forming oligonucleotides as modulators of gene expression. Int J Biochem Cell Biol 2003; 35: 22-31.
4. Nielsen PE. Targeting double stranded DNA with peptide nucleic acid (PNA). Curr Med Chem 2001; 8: 545-50.
5. Tamm I, Dorken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet 2001; 358: 489-97.
6. Sun LQ, Cairns MJ, Saravolac EG, Baker A, Gerlach WL. Catalytic nucleic acids: from lab to applications. Pharmacol Rev 2000; 52: 325-47.
7. Cerchia L, Hamm J, Libri D, Tavitian B, de Franciscis V. Nucleic acid aptamers in cancer medicine. Febs Lett 2002; 528: 12-26.
8. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitirs abd cancer therapy:lessons from mechanism and bench-to-bed side translational studies. Oncogene 2000; 19: 6584-93.
9. Tuschl T. RNA interference and small interfering RNAs. Chembiochem 2001; 2: 239-45.
10. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-98.
11. Warshaw AL, Fernandez-del Castello C. Pancreatic carcinoma. New Engl J Med 1992; 326: 455-65.
12. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002; 3: 101-28.
13. Nesbit CE, Tersak JM, Prochownik E. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004-16.
14. Kozma L, Kiss I, Hagy A, Szakall S, Ember I. Investigation of c-myc and K-tas amplification in renal clear cell adenocarcinoma. Cancer Lett 1997; 111: 127-31.
15. Moser HE, Dervan PB. Sequenee-specific cleavage of double helical DNA by triple helix formation. Science 1987; 238: 456-50.
16. Cooney M, Czernuszewicz G, Postel EH, Flint SJ, Hogan ME. Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science 1988; 241: 456-9.
17. Beal PA, Dervan PB. Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation. Science 1991; 251: 1360-3.
18. Doronina SO, Beher JP. Towards a general triple helix mediated DNA recognition scheme. Chem Soc Rev 1997; 26: 63-71.
19. Praseuth D, Guieysse AL, Hélène C. Triple helix formation and the antigene strategy for sequence-specific control of gene expression. Biochim Biophys Acta 1999; 1489: 181-206.
20. Knauert MP, Glazer M. Triplex forming oligonucleotides: sequence-specific tools for gene targeting. Hum Mol Genet 2001; 10: 2243-51.
21. Manzini G, Gasparotto D, Quadrifoglio F, van der Marel GA, van Boom JH. Triple helix formation by oligopurine-oligopyrimidine DNA fragments. Electrophoretic and thermodynamic behavior. J Mol Biol 1990; 231: 833-43.
22. Xodo LE, Manzini G, Quadrifoglio F. Spectroscopic and calorimetric investigation on the DNA triplex formed by d(CTCTT CTTTCTTTTCTTTCTTCTC) and d(GAGAAGAAAGA. Nucleic Acids Res 1990; 18: 3557-64.
23. Pilch DS, Brousseau R, Shafer RH. Thermodynamics of triple helix formation: spectrophotometric studies on the d(A)10.2d(T)10 and d(C+3T4C+3).d(G3A4G3).d(C3T4C3) triple helices. Nucleic Acids Res 1990; 18: 5743-50.
24. Lee JS, Woodsworth ML, Latimer LJ, Morgan AR. Poly(pyrimidine). poly(purine) synthetic DNAs containing 5-methylcytosine form stable triplexes at neutral pH. Nucleic Acids Res 1984; 12: 6603-14.
25. Xodo LE, Manzini G, Quadrifoglio F, van der Marel GA, van Boom JH. Effect of 5-methylcytosine on the stability of triple-stranded DNA - a thermodynamic study. Nucleic Acids Res 1991; 19: 5625-31.
26. Dagle JM, Weeks DL. Oligonucleotide-based strategies to reduce gene expression. Differentiation 2001; 69:75-82.
27. Vasquez KM, Glazer PM. Triplex-forming oligonucleotides: principles and applications. Q Rev Biophys 2002; 35: 89-107.
28. Casey BP, Glazer PM. Gene targeting via triple-helix formation. Prog Nucleic Acid Res 2001; 67: 163-92
29. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 1996; 14: 376-87.
30. Cheng A J, van Dyke MW. Monovalent cation effects on intermolecular purine-purine-pyrimidine triple-helix formation. Nucleic Acids Res 1993; 21: 5630-35.
31. Alunni-Fabbroni M, Manzini G, Quadrifoglio F, Xodo LE. Guanine-rich oligonucleotides targeted to a critical R. Y site located in the Ki-ras promoter. The effect of competing self-structures on triplex formation. Eur J Biochem 1996; 238: 141-51.
32. Nagel KM, Holstad SG, Isenberg KE. Oligonucleotide pharmacotherapy: an antigene strategy.Pharmacotherapy 1993; 13: 177-88.
33. Milligan JF, Krawczyk SH, Wadwani S, Matteucci MD. An anti-parallel triple helix motif with oligodeoxynucleotides containing 2′-deoxyguanosine and 7-deaza-2′-deoxyxanthosine. Nuclei Acids Res 1993; 21: 327-33.
34. Faruqi AF, Krawczyk SH, Matteucci MD, Glazer PM. Potassium-resistant triple helix formation and improved intracellular gene targeting by oligodeoxyribonucleotides containing 7-deazaxanthine. Nucleic Acids Res 1997; 25: 633-40.
35. Rao TS, Durland RH, Seth DM, Myrick MA, Bodepudi V, Revankar GR. Incorporation of 2′-deoxy-6-thioguanosine into G-rich oligodeoxyribonucleotides inhibits G-tetrad formation and facilitates triplex formation. Biochemistry 1995; 34: 765-72.
36. Olivas WM, Maher LJ. Overcoming potassium-mediated triplex inhibition. Nucleic Acids Res 1995; 23: 1936-41.
37. Dagle, JM, Weeks DL. Positively charged oligonucleotides overcome potassium-mediated inhibition of triplex DNA formation. Nucleic Acids Res 1996; 24: 2143-49.
38. Aubert Y, Perrouault L, Hélène C, Giovannangeli C, Asseline U. Synthesis and properties of triple helix-forming oligodeoxyribonucleotides containing 7-chloro-7-deaza-2′-deoxyguanosine. Bioorgan Med Chem 2001; 9: 1617-24.
39. Eckstein F. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev 2000; 10: 117-21.
40. Schultz RG, Gryaznov SM. Oligo-2′-fluoro-2′-deoxynucleotide N3′->P5′ phosphoramidates: synthesis and properties. Nucleic Acids Res 1996; 24: 2966-73.
41. Sun JS, Garestier T, Hélène C. Oligonucleotide directed triple helix formation. Curr Opin Struct Biol 1996; 6: 327-33.
42. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997; 7: 187-95.
43. Basye J, Trent JO, Gao D, Ebbinghaus SW. Triplex formation by morpholino oligodeoxyribonucleotides in the HER-2/neu promoter requires the pyrimidine motif. Nucleic Acids Res 2001; 29: 4873-80.
44. Cassidy RA, Kondo NS, Miller PS. Triplex formation by psoralen-conjugated chimeric oligonucleoside methylphosphonates. Biochemistry 2000; 39: 8683-91.
45. Petersen M, Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol 2003; 21: 74-81.
46. Obika S, Uneda T, Sugimoto T, Nanbu D, Minami T, Doi T, et al. 2′-O,4′-C-Methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties. Bioorg Med Chem 2001; 9: 1001-11.
47. Lacroix L, Lacoste J, Reddoch JF, Mergny JL, Levy DD, Seidman MM, et al. Triplex formation by oligonucleotides containing 5-(1-propynyl)-2′-deoxyuridine: decreased magnesium dependente and improved intracellular gene targeting. Biochemistry 1999; 38: 1893-901.
48. Majumdar A, Khorlin A, Dyatkina N, Lin FL, Powell J, Liu J, et al. Targeted gene knockout mediated by triple helix forming oligonucleotides. Nat. Genet 1998; 20: 212-4.
49. Puri N, Majumdar A, Cuenoud B, Natt F, Martin P, Boyd A, et al. Targeted gene knockout by 2′-O-aminoethyl modified triplex forming oligonucleotides. J Biol Chem 2001; 276: 28991-98.
50. Nielsen PE, Eghomlm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991; 254: 1497-50.
51. Bukanov NO, Demidov VV, Nielsen PE, Frank-Kamenetskii MD. PD-loop: a complex of duplex DNA with an oligonucleotide. Proc Natl Acad Sci USA 1998; 95: 5516-20.
52. Hanvey JC, Peffer NJ, Bisi JE, Thomson SA, Cadilla R, Josey JA, et al. Antisense and antigene properties of peptide nucleic acids. Science 1992; 258: 1481-5.
53. White S, Szewczyyk JW, Turner JM, Baird EE, Dervan PB. Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands. Nature 1998; 391: 468-71.
54. Maher LJ. Inhibition of T7 RNA polymerase initiation by triple-helical DNA complexes: a model for artificial gene repression. Biochemistry 1992; 31: 7587-94.
55. Young SL, Krawczyk SH, Matteucci MD, Toole J.J. Triple helix formation inhibits transcription elongation in vitro. Proc Natl Acad Sci USA 1991; 88: 10023-26.
56. Postel EH, Flint SJ, Kessler DJ, Hogan ME. Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc Natl Acad Sci USA 1991; 88: 8227-31.
57. Thoma TJ, Faaland, CA, Gallo MA, Thomas T. Suppression of c-myc oncogene expression by a polyamine-complexed triplex forming oligonucleotide in MCF-7 breast cancer cells. Nucleic Acids Res 1995; 23: 3594-99.
58. Dagle, JL, Walder J, Weeks DL. Targeted degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis. Nacl. Acids Res 1990; 18: 4751-57.
59. Catapano CV, McGuffie EM, Pacheco D, Carbone GM. Inhibition of gene expression and cell proliferation by triple helix-forming oligonucleotides directed to the c-myc gene. Biochemistry 2000; 39: 5126-38.
60. Mc Guffie EM, Pacheco D, Carbone GMR, Catapano CV. Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells. Cancer Res 2000; 60: 3790-99.
61. Tu GC, Cao QN, Israel Y. Inhibition of gene expression by triple helix formation in hepatoma cells. J Biol Chem 1995; 24: 28402-07.
62. Marchand P, Resch K, Radeke HH. Selective inhibition of monocyte chemoattractant protein-1 gene expression in human embryonal kidney cells by specific triple helix-forming oligonucleotides. J Immunol 2000; 164: 2070-77.
63. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993; 261: 1004-12.
64. Cogoi S, Rapozzi V, Quadrifoglio F, Xodo L. Anti-gene effect in live cells of AG motif triplex-forming oligonucleotides containing an increasing number of phosphorothioate linkages. Biochemistry 2001; 40: 1135-43.
65. Wang G, Levy DD, Seidman MM, Glazer PM. Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation. Mol Cell Biol 1995; 15: 1759-68.
66. Carbone GM, McGuffie EM, Collier A, Catapano CV. Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide. Nucleic Acids Res 2003; 31: 833-43.
67. McGuffie EM, Catapano CV. Design of a novel triple helix-forming oligodeoxyribonucleotide directed to the major promoter of the c-myc gene. Nucleic Acids Res 2002; 30: 2701-09.
68. Klysik J, Kinsey BM, Hua P, Glass GA, Orson FM. 15-base acridine-conjugated oligodeoxynucleotide forms triplex DNA with its IL-2R alpha promoter target with greatly improved avidity. Bioconjug Chem 1997; 8: 318-26.
69. Silver GC, Nguyen CH, Boutorine AS, Bisagni E, Garestier T, Helene C. Conjugates of oligonucleotides with triplex-specific intercalating agents. Stabilization of triple-helical DNA in the promoter region of the gene for the alpha-subunit of interleukin 2 (IL-2R alpha). Bioconjug Chem 1997; 8: 15-22.
70. Escude C, Nguyen CH, Kukreti S, Janin Y, Sun JS, Bisagni E, et al. Rational design of a triple helix-specific intercalating ligand. Proc Natl Acad Sci USA 1998; 95: 3591-6.
71. Kukreti S, Sun JS, Loakes D, Brown DM, Nguyen CH, Bisagni E, et al. Triple helices formed at oligopyrimidine*oligopurine sequences with base pair inversions: effect of a triplex-specific ligand on stability and selectivity. Nucleic Acids Res 1998; 26: 2179-83.
72. Musso M, Wang JC, Van Dyke MW.In vivo persistence of DNA triple helices containing psoralen-conjugated oligodeoxyribonucleotides. Nucleic Acids Res 1996; 24: 4924-32.
73. Puri N, Majumdar A, Cuenoud B, Natt F, Martin P, Boyd A, et al. Targeted gene knockout by 2′-O-aminoethyl modified triplex forming oligonucleotides. J Biol Chem 200; 276:28991-8.
74. Besch R, Giovannangeli C, Kammerbauer C, Degitz K. Specific inhibition of ICAM-1 expression mediated by gene targeting with Triplex-forming oligonucleotides. J Biol Chem 2002; 277:32473-9.
75. Dass CR. Liposome-mediated delivery of oligodeoxynucleotides in vivo. Drug Deliv 2002; 9: 169-80.
76. Manoharan M. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev 2002; 12: 103-28.
77. Bennett CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 1992; 41: 1023-33.
78. Zelphati O, Szoka FC Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 1996; 93: 11493-98.
79. Mayer O, Kirpotin D, Hong K, Sternberg B, Park JW, Woodle MC, et al. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J Biol Chem 1998; 273: 15621-27.
80. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 2000; 97: 8548-53.
81. Arnold K, Pratsch L, Gawrisch K. Effect of poly(ethylene glycol) on phospholipid hydration and polarity of the external phase. Biochim Biophys Acta 1983; 728: 121-28.
82. Bonora GM, Ivanocva E, Zarytova V, Burcovich B, Veronese M. Synthesis and characterization of high-molecular mass polyethylene glycol-conjugated oligonucleotides. Bioconjugate Chem 1997; 8: 793-97.
83. Ballico M, Drioli S, Morvan F, Xodo L, Bonora GM. Triple, MPEG-conjugated, helix-forming oligonucleotides (TRIPEGXs): liquid-phase synthesis of natural and chimeric "all-purine" sequences linked to high molecular weight poly(ethylene glycols). Bioconjugate Chem 2001; 12: 719-25.
84. Vorobjev PE, Zarytova VF, Bonora GM. Oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycol as substrates for RNase H. Nucleosides Nucleotides 1999; 18: 2745-50.
85. Jaschke A, Furste JP, Nordhoff E, Hillenkamp F, Cech D, Erdmann VA. Synthesis and properties of oligodeoxyribonucleotide-polyethylene glycol conjugates. Nucleic Acids Res 1994; 22: 4810-17.
86. Vorobjev PE, Pyshnaya IA, Pyshnyi DV, Venyaminova AG, Ivanova EM, Zarytova VF, et al. Nuclease resistance and RNase H sensitivity of oligonucleotides bridged by oligomethylenediol and oligoethylene glycol linkers. Antisense Nucleic Acid Drug Dev 2001; 11: 77-85.
87. Mayfield C, Squibb M, Miller D. Inhibition of nuclear protein binding to the human Ki-ras promoter by triplex-forming oligonucleotides. Biochemistry 1994; 33: 3358-63.
88. Rapozzi V, Cogoi S, Spessotto P, Risso A, Bonora GM, Quadrifoglio F, et al. Antigene effect in K562 cells of a PEG-conjugated triplex-forming oligonucleotide targeted to the bcr/abl oncogene. Biochemistry 2002; 41: 502-10.
89. Wang S, Kool ET. Origins of the large differences in stability of DNA and RNA helices: C-5 methyl and 2′-hydroxyl effects. Biochemistry 1995; 34:4125-32.
90. Estude C, Francois JC, Sun JS, Ott G, Sprinzl M, Garestier T, et al. Stability of triple helices containing RNA and DNA strands: experimental and molecular modeling studies. Nucleic Acids Res 1993; 21:5547-53.
91. Roberts RW, Crothers DM. Stability and properties of double and triple helices: dramatic effects of RNA or DNA backbone composition. Science 1992; 258: 1463-66.
92. Han H, Dervan PB. Different conformational families of pyrimidine.purine.pyrimidine triple helices depending on backbone composition. Nucleic Acids Res 1994; 22: 2837-44.
93. Ririe SS, Guntaka RV. An RNA oligonucleotide corresponding to the polypyrimidine region of the rat alpha 1(I) procollagen promoter forms a stable triplex and inhibits transcription. Biochem Bioph Res Com 1998; 249: 218-21.
94. Cogoi S, Suraci C, Del Terra E, Diviacco S, van der Marel G, van Boom J, et al. Downregulation of c-Ki-ras promoter activity by triplex-forming oligonucleotides endogenously generated in human 293 cells. Antisense Nucleic Acid Drug Dev 2000; 10: 283-95.
95. Noonberg SB, Scott GK, Hunt CA, Hogan ME, Benz CC. Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligodeoxyribonucleotides. Gene 1994; 149: 123-6.
96. Rininsland F, Johnson TR, Chernicky CL, Schulze, E, Burfeinfd P, Ilan J. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc Natl Acad Sci USA 1997; 94: 5854-59.
97. Chen Y, Ji YJ, Roxby R, Conrad C. In vivo expression of single-stranded DNA in mammalian cells with DNA enzyme sequences targeted to C-raf. Antisense Nucleic Acid Drug Dev 2000; 10: 415-22.
98. Datta HJ, Glazer PM. Intracellular generation of single-stranded DNA for chromosomal triplex formation and induced recombination. Nucleic Acids Res 2001; 29: 5140-47.
99. Egholm M, Buchardt O, Christense L, Beherens C, Freier SM, Driver DA, et al. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 1993; 365: 566-68.
100. Wittung P, Nielsen PE, Buchardt O, Egholm M, Norden B. DNA-like double helix formed by peptide nucleic acid. Nature 1994; 368:561-63.
101. Uhlmann E, Peyman A, Breipohl G, Will DW. PNA: synthetic polyamide nucleic acids with unusual binding properties. Ange Chem Int Ed 1998; 37: 2896-23.
102. Tomac S, Sarkar M, Ratilainen T, Wittung P, Nielsen PE, Norden B, et al. Ionic effects on the stability and conformation of peptide nucleic acid complexes. J Am Chem Soc 1996; 118: 5544-5552.
103. Ray A, Norden B. Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future. FASEB J 2000; 14: 1041-60.
104. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence specific inhibition of DNA restriction enzyme cleavage by PNA. Nuclear Acids Res 1993; 21: 197-200.
105. Nielsen PE, Egholm M, Buchardt O. Sequence-specific transcription arrest by peptide nucleic acid bound to the DNA template strand. Gene 1994; 149: 139-45.
106. Loshe J, Dahl O, Nielsen PE. Double duplex invasion by peptide nucleic acid: a general principle for sequence-specific targeting of double-stranded DNA. Proc Natl Acad Sci USA 1999; 96: 11804-08.
107. Boffa LC, Carpaneto EM, Allfrey VG. Isolation of active genes containing CAG repeats by DNA strand invasion by a peptide nucleic acid. Proc Natl Acad Sci USA 1995; 92: 1901-07.
108. Faruqi AF, Egholm M, Glazer PM. Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells. Proc Natl Acad Sci USA 1998; 95: 1398-403.
109. Bentin T, Nielsen PE. Enhanced peptide nucleic acid binding to supercoiled DNA: possible implications for DNA "breathing" dynamics. Biochemistry 1996; 35: 8863-69.
110. Boffa LC, Carpaneto EM, Mariani MR, Louissaint M, Allfrey VG. Contrasting effects of PNA invasion of the chimeric DMMYC gene on transcription of its myc and PVT domains. Oncol Res 1997; 9: 41-51.
111. Wittung P, Kajanus J, Edwards K, Haaima G, Nielsen PE, Norden B, et al. Phospholipid membrane permeability of peptide nucleic acid. Febs Lett 1995; 375: 27-9.
112. Aldrian-Herrada G, Desarmenien MG, Orcel H, Boissin-Agasse L, Mery J, Brugidou J, et al. A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retroinverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons. Nucleic Acids Res 1998; 26: 4910-16.
113. Tyler BM, Jansen K, McCormick DJ, Douglas CL, Boules M, Stewart JA, et al. Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. Proc Natl Acad Sci USA 1999; 96: 7053-58.
114. Rapozzi V, Burm BE, Cogoi S, van der Marel GA, van Boom JH, Quadrifoglio F, et al. Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids. Nucleic Acids Res 2002; 30: 3712-21.
115. Koppelhus U, Nielsen PE. Cellular delivery of peptide nucleic acid (PNA). Adv Drug Deliv Rev 2003; 55: 267-80.
116. Cutrona G, Carpaneto EM, Ulivi M, Rondella S, Landt O, Ferrarini M, et al. Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat Biotechnol 2000; 18: 300-03.
117. Kalderon D, Roberts BL, Richardson WD, Smith AE. A short amino acid sequence able to specify nuclear location. Cell 1984; 39: 499-509.
118. Gorlich D, Mattaj IW. Nucleocytoplasmic transport. Science 1996; 271: 1513-18.
119. Cogoi S, Rapozzi V, Xodo LE. Inhibition of gene expression by peptide nucleic acids in cultured cells Nucleosides, Nucleotides & Nucleic Acids 2003; 22: 1615-17
120. Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, Rezaei K, et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol 1998; 16: 857-61.
121. Basu S, Wickstrom E. Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconjugate Chem 1997; 8: 481-88.
122. Ljungstrom T, Knudsen H, Nielsen PE. Cellular uptake of adamantyl conjugated peptide nucleic acids. Bioconjugate Chem 1999; 10: 965-72.
123. Pardridge W, Boado RJ, Kang YS. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci USA 1995; 92: 5592-96.
124. Gangamani BP, Kumar VA, Ganesh NK. Spermine conjugated peptide nucleic acids (spPNA): UV and fluorescence studies of PNA-DNA hybrids with improved stability. Biochem Biophys Res Commun 1997; 240: 778-82.
125. Zhang X, Simmons CG, Corey DR. Liver cell specific targeting of peptide nucleic acid oligomers. Bioorg Med Chem Lett 2001; 11: 269-72.
126. Gambari R. Peptide-nucleic acids (PNAs): a tool for the development of gene expression modifiers. Curr Pharm Design 2001; 7(17): 1839-62.
127. Shih C, Teicher BA. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. Curr Pharm Design 2001; 7(13): 1259-76.
128. Youngster S, Wang YS, Grace M, Bausch J, Bordens R, Wyss DF. Structure, biology, therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Design 2002; 8(24): 2139-57.